Valerio Therapeutics Société anonyme (FRA:C4X)

Germany · Delayed Price · Currency is EUR

0.161

-0.005 (-3.01%)

At close: Dec 4, 2025

122.68% (1Y)

Market Cap	80.17M
Revenue (ttm)	1.83M
Net Income (ttm)	-13.18M
Shares Out	n/a
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7,750
Open	0.161
Previous Close	0.166
Day's Range	0.161 - 0.161
52-Week Range	0.030 - 0.280
Beta	n/a
RSI	55.15
Earnings Date	Dec 29, 2025

About FRA:C4X

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, generates DecoyTAC combining DNA decoy molecules capable of cell penetration with a linker+E3 ligand. It also develops V-body platform, a bis... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1997

Employees 38

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol C4X

Full Company Profile

Financial Performance

In 2024, FRA:C4X's revenue was 1.79 million, a decrease of -0.39% compared to the previous year's 1.80 million. Losses were -23.93 million, 17.6% more than in 2023.

Financial Statements

News

There is no news available yet.